Clinical Trial Update: Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating bortezomib for refractory chronic graft-versus-host disease, sponsored by Baylor Research Institute. The trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Baylor Research Institute | Conditions: Chronic Graft-versus-host Disease | Phase 2 | Status: UNKNOWN